Domino Company Spotlight
Domino Integrated Solutions Group
The Integrated Solutions Group of Domino Printing Sciences Plc is a leading innovator of technologies and full solutions that provide robust traceability and product security systems. Domino offers a full integration service that extends from initial needs-based consultation, technology evaluation and testing through to full system implementation. By integrating the leading AIDC (automatic identification and data capture) technologies available and combining these with a data management platform that extends from control over data flows within the enterprise, to transfer to external parties, the company offers an extensive range of modular and scalable track & trace systems. Configurable RFID packages are available that can provide immediate cost benefit and enable customers to avoid unnecessary costs associated with RFID implementation programmes.
Domino offers a range of solutions specific to the pharmaceutical market. Its specialists are trained to understand the needs of the pharmaceutical industry and identify the coding and traceability solutions required for each customer within the supply chain. Both ink jet and laser products can be supplied with validation packs for GAMP and 21-CFR part 11 compliance. Domino's technology and integrated solutions are utilised by major manufacturers for product traceability and anti-counterfeiting measures in applications that include the laser scribing of tablet cartons and blister packs and the direct marking of individual tablets and capsules. In addition, its integrated solutions can be deployed across the entire supply chain to ensure item level identification from original product manufacture right through to delivery to the individual patient.
Contact Details
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.